SCN2A-Related Epilepsy

SCN2A-related epilepsy describes a spectrum of neurological disorders caused by pathogenic variants in SCN2A, which encodes the Nav1.2 voltage-gated sodium-channel alpha subunit. The spectrum includes self-limited infantile epilepsy, developmental and epileptic encephalopathy (DEE), autism and intellectual disability with or without epilepsy.

The most important clinical point is that not all SCN2A variants behave in the same way. Gain-of-function and loss-of-function variants can produce different phenotypes and may have different treatment implications.

What SCN2A does

Nav1.2 channels are important for neuronal action-potential initiation and propagation, particularly during early brain development.

Pathogenic variants can either increase channel activity, reduce it, or alter channel function in more complex ways.

Early-onset epilepsy and gain of function

Severe epilepsy beginning in the neonatal period or early infancy is commonly associated with gain-of-function SCN2A variants.

Seizures can be focal, multifocal or bilateral convulsive and may occur many times per day.

Later neurodevelopmental phenotypes

Loss-of-function variants are more commonly associated with autism, developmental delay or intellectual disability, sometimes with later-onset epilepsy or no epilepsy at all.

This genotype–phenotype relationship is not absolute and specialist interpretation remains essential.

Self-limited neonatal-infantile epilepsy

Some SCN2A variants cause relatively mild familial neonatal-infantile epilepsy in which focal seizures begin early and later remit.

Normal development is expected in the classic self-limited phenotype.

Developmental and epileptic encephalopathy

At the severe end of the spectrum, seizures begin very early and are often drug resistant.

Developmental impairment can reflect both the underlying channel disorder and the effect of frequent seizures and epileptiform activity.

EEG

EEG findings vary with phenotype and age. Focal or multifocal epileptiform discharges, background slowing and severe neonatal patterns may occur.

No single EEG pattern is specific to SCN2A.

MRI

MRI is often normal but may show non-specific developmental or atrophic changes in severe cases.

Imaging remains important to exclude structural causes of early-life seizures.

Why functional testing matters

Two different SCN2A variants can affect the same protein in opposite directions.

Functional interpretation from laboratory studies, variant location, phenotype and published evidence can therefore influence treatment decisions.

Sodium-channel blockers

In early-onset gain-of-function SCN2A epilepsy, sodium-channel-blocking medicines such as phenytoin, carbamazepine, oxcarbazepine or lacosamide may be particularly effective in some individuals.

This should not be generalised to all SCN2A disorders.

Loss-of-function caution

When the phenotype is driven by loss of channel function, further sodium-channel blockade may be unhelpful or potentially worsen the clinical picture.

Treatment should therefore be based on phenotype and molecular mechanism rather than the gene name alone.

Other treatments

Other broad-spectrum and focal antiseizure medicines may be used according to seizure type and response.

Ketogenic dietary therapy can also be considered in drug-resistant cases.

Precision medicine research

SCN2A is a major target for gene-based and molecular therapies, including approaches designed either to reduce excessive channel activity or restore insufficient function.

Most of these approaches remain investigational.

Development, movement and behaviour

Severe SCN2A-related disorders can involve hypotonia, movement abnormalities, cortical visual impairment, feeding difficulties, sleep problems and autism spectrum features.

Support therefore needs to extend beyond seizure control.

Inheritance

Severe SCN2A-DEE variants are often de novo, while milder familial epilepsy can be inherited in an autosomal-dominant pattern.

Parental mosaicism can affect recurrence risk.

Worldwide access

SCN2A illustrates why access to genomic testing matters in epilepsy. Without a molecular diagnosis, potentially mechanism-specific treatment opportunities may be missed.

However, functional interpretation remains available only in specialist or research settings in many countries.

The central point

SCN2A is not one epilepsy. It is a spectrum in which the functional direction of the variant—especially gain versus loss of function—can influence phenotype and treatment.

Sources

Medical note: treatment should not be chosen from the gene name alone. Variant mechanism and clinical phenotype matter.

Evidence checked: September 2026.